Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories maintains a low beta value.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories shows active trading performance
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories closed at 1322.9 yesterday.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories finished the day at 1322.9.
Dr Reddy's gets Health Canada nod for generic semaglutide injection
Dr Reddy's Laboratories has secured market authorization from Health Canada for its generic semaglutide injection. This marks a significant achievement as the first company to receive approval for this diabetes treatment in Canada. The company is now preparing to launch the medication, aiming to provide Canadian patients with access to this important therapy.
Market Trading Guide: Buy Dr Reddy’s Laboratories and Solar Industries on Friday for gains up to 14%
Nifty extended losses amid weakness in key sectors, facing resistance near moving averages. Analysts highlight a crucial trading range for direction while recommending select stocks showing bullish breakouts, strong momentum, and accumulation supported by rising volumes
Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say
Analysts who track Dr. Reddy's expect six to nine months of no competition in the Canadian market and that the street is working with revenue between $80 million to $100 million in Canada for financial year 2027.
Explained — Why Dr. Reddy's Laboratories shares are down in a strong market
Citi said the rejection prevents Dr. Reddy's Laboratories from participating in the initial wave of semaglutide in Brazil. Dr. Reddy's has missed the early opportunity in a competitive market with 16 pending applications in Brazil, Citi's note said.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories faces a weekly return drop
Dr Reddy's partner Immutep told to halt phase III trial of lung cancer drug eftilagimod alfa
Enrolment in the study is being halted in response to the Independent Data Monitoring Committee's recommendation. Shares of Dr Reddy's Laboratories Ltd ended at ₹1,288.40, down by ₹30.35, or 2.30%, on the BSE today, March 13.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories sees a healthy return
